Does EBO2 (EBOO) Work? What the Published Research Reports
EBO2 (also called EBOO) has a published research record that begins in 2000. Researchers have reported on it in a randomized trial of 28 people with peripheral artery disease, in case reports on individual patients, in a review by the developers that describes more than 1,200 treatments in 82 patients, and in measurements of how much ozone the blood takes up during a session [1][2][3][4][6][7].
This guide walks through those papers one at a time: who was studied, what was measured, and what the authors reported. Each study name opens our notes on it in the research library, and the studies compared report sorts the same library by study design.
Where the research comes from
EBOO was developed by nephrology and physiology researchers in Siena, Italy. Four of the six papers on the procedure as given to people come from that group [1][2][3][4]. The other two come from clinicians in the United States: doctors at a Santa Rosa, California clinic [7] and clinicians at a New York pain-management practice [6].
The Siena group also published the work that built the circuit. It tested equipment in saline, pig blood, and sheep [8]. It compared several oxygenators with human blood outside the body and selected one type, reporting that the newer devices treated up to 5 liters in about an hour [9]. It later bench-tested a new gas exchange device, which it described as “very versatile and efficient” [5], and measured how well ozone passed through four dialysis filters and a purpose-built gas exchanger [10].
By 2005 the developers described treating up to 4,800 ml of blood in one hour of circulation [3]. Our history of EBO2 and EBOO vs dialysis guides cover the equipment in more detail.
The studies of EBOO in people
| Study | Who took part | What was measured | What the paper reported |
|---|---|---|---|
| Di Paolo et al., 2000 | A first report with no patient count: one author who volunteered, “a patient with Madelung disease and several patients with atherosclerotic vasculopathy” [1] | The first experience of the treatment in people | Two lipomas disappeared in the volunteer after six treatments. The authors call the results therapeutic and “without side-effects” [1] |
| Di Paolo et al., 2002 | One dialysis patient with necrotizing fasciitis, after “traditional therapies were unsuccessful” [2] | The patient’s condition | “Patient condition improved radically after EBOO” [2] |
| Di Paolo et al., 2005, review | A review by the developers, citing “more than 1200 treatments performed in 82 patients” [3] | Blood markers after a session | Thiobarbituric acid reactants rose four- to fivefold and plasma protein thiols fell, “without any appreciable erythrocyte haemolysis”. The standard course was 14 one-hour sessions over 7 weeks [3] |
| Di Paolo et al., 2005, trial | 28 people with peripheral artery disease, randomized to EBOO or intravenous prostacyclin at one hospital [4] | Skin lesions, pain, quality of life, and blood supply to the legs | “Highly significant regression of skin lesions” with EBOO compared with prostacyclin. Pain, pruritus, heavy legs, and well-being also differed between the groups. Leg vascularisation did not change significantly in either group. No side effects were recorded in 210 EBOO treatments [4] |
| Rowen et al., 2023 | 12 patients during routine treatment at the authors’ clinic, 85 measurements [7] | Ozone taken up by the blood | Average uptake of 37% of the generator’s output, with a range of 25 to 50%. The authors calculate about 460,000 μg in a one-hour treatment at 30 μg/mL [7] |
| Bennett et al., 2025 | One 88-year-old woman with chronic anemia, given two series of three treatments with about 2 liters of blood processed each time [6] | Urinary toxin-to-creatinine ratios on days 0, 70, and 131, and hemoglobin | Average declines of 64.8% for mycotoxins, 25.7% for heavy metals, and 55.1% for environmental toxins. Nickel was “the only toxin that showed an overall increase”. Hemoglobin was 7.4, 6.8, and 7.5 g/dL, and she reported feeling worse after the second series [6] |
The randomized trial
The 2005 trial is the one study that compared EBOO with another treatment. Its 28 participants had peripheral artery disease and were randomized to EBOO or to intravenous prostacyclin. The paper reports “highly significant regression of skin lesions” in the EBOO group, differences between the groups in pain, pruritus, heavy legs, and well-being, and no significant change in leg vascularisation in either group [4]. It also records no side effects across 210 EBOO treatments [4].
The case reports
Two papers each follow one patient. The 2002 report describes a dialysis patient with necrotizing fasciitis whose condition “improved radically after EBOO”, after traditional therapies had been unsuccessful [2]. The 2025 report tracked toxins in the urine of an 88-year-old woman across two series of treatments and recorded average declines in mycotoxins, heavy metals, and environmental toxins, with nickel as the one overall increase [6]. A case report describes what happened for one person.
The session measurements
Two papers describe what happens during a session. The developers’ 2005 review reports changes in blood oxidation markers after treatment “without any appreciable erythrocyte haemolysis” [3]. The 2023 California series, which calls the procedure “ozone dialysis” and says it is “commonly referred to as” EBOO, found that blood took up an average of 37% of the ozone the generator produced [7]. Its authors add that their clinic had run “at least 400 sessions” “with no untoward effects observed” [7].
What the wider ozone research adds
A larger group of studies looks at ozone given other ways. The most common is major autohemotherapy, which usually draws about 200 mL of blood into a bag and mixes it with ozone [7]. Others use injections. These are related procedures with a different route and dose from EBO2, so read them as context for ozone therapy in general.
- Eyesight. A randomized open trial of major autohemotherapy enrolled 140 people with dry age-related macular degeneration. At 12 months, 25% of treated eyes had gained a line of acuity against 0% of untreated eyes [11].
- Back pain. A review of 8 observational studies and 4 randomized trials of ozone injected into or beside spinal discs reported a pooled odds ratio of 2.66 in favor of ozone [12].
- Wound healing. A review of 12 trials in chronic wounds reported faster wound-area improvement and fewer amputations for diabetic foot ulcers, with no difference in complete healing or hospital stay [14].
- Post-COVID fatigue. In a series of 100 people given major autohemotherapy, the mean fatigue score fell by 67% [13]. A pilot randomized trial of 73 people reported a response in 25 of 35 (71%) who had major autohemotherapy with usual care, against 17 of 38 (45%) who had usual care alone [15]. A record review of 40 people reported better fatigue, anxiety, depression, and some quality-of-life scores after 10 sessions [16].
- Tolerability. A randomized trial of 118 people that combined ozonated autohemotherapy with medicine for insomnia and myofascial pain observed no adverse complications in either group [17].
What this means if you are considering EBO2
The published papers on EBOO report four kinds of outcome: skin lesions and symptoms in people with peripheral artery disease [4], the course of an individual patient’s illness [2], laboratory markers in blood and urine [3][6], and how much ozone the blood takes up in a session [7]. If your reason for looking at EBO2 is close to one of those, the linked study notes are worth reading in full.
The papers also give a sense of how treatment is scheduled. The developers’ standard course was 14 one-hour sessions over 7 weeks [3], and the 2025 case used two series of three treatments [6]. Our how many sessions guide covers how clinics schedule a course.
Three of the papers comment on how people tolerated the procedure. The 2000 report describes it as “without side-effects” [1], the trial recorded none in 210 treatments [4], and the California authors observed no untoward effects in at least 400 sessions [7]. Our side effects and safety guide goes through this topic in full.
Results for an individual vary. The EBOO studies are small, the largest has 28 people [4], and no study can say how one person will respond. A good next step is to read what to expect from a session and to talk with a clinic about your goals. You can compare providers in our clinic directory.
Good to know
Ozone therapy, including EBO2, is not FDA-approved. Talk to your doctor before you book, tell the clinic about your health conditions and every medicine you take, and keep taking any treatment you have been prescribed. Our contraindications and blood thinners and medications guides explain who should check first.
From our data
The procedure as the EBOO studies report it
| Study | Participants | Sessions | Session length | Blood treated |
|---|---|---|---|---|
| Observed Reduction in Urinary Toxin Excretion With Extracorporeal B..., 2025 | 1 person | Two distinct series of three sequential EBOO treatments; urinary toxin/creatinine ratios monitored at baseline, after series I and after series II | Not reported | Around 2 liters of blood processed in one treatment (clinic protocol) |
| Ozone dialysis delivers three or more times the ozone than other fo..., 2023 | 12 people | Not reported | exactly 1 hour | Not reported |
| Extracorporeal blood oxygenation and ozonation: clinical and biolog..., 2005 | Not reported | 14 sessions over 7 weeks (the standard therapeutic cycle) | 1 h per session | Up to 4800 ml of heparinized blood in 1 h of extracorporeal circulation |
| Extracorporeal blood oxygenation and ozonation (EBOO): a controlled..., 2005 | 28 people | 210 EBOO treatments (per-patient schedule not stated in the abstract) | Not reported | Not reported |
| Necrotizing fasciitis successfully treated with extracorporeal bloo..., 2002 | 1 person | Not reported | Not reported | Not reported |
| Extracorporeal blood oxygenation and ozonation (EBOO) in man. preli..., 2000 | Not reported | six treatments (volunteer author); not stated for the patients | Not reported | Not reported |
Figures are as the papers state them, with their own units. All studies side by side.
Frequently asked questions
Are there published studies of EBO2?
Yes. Six papers describe EBOO as given to people, starting with a preliminary report in 2000. They include a randomized trial of 28 people with peripheral artery disease, two case reports, a review by the developers describing more than 1,200 treatments in 82 patients, and ozone-uptake measurements in 12 patients at a California clinic.
What did the EBOO trial report?
The 2005 trial compared EBOO with intravenous prostacyclin in 28 people with peripheral artery disease. The paper reports highly significant regression of skin lesions in the EBOO group, no significant change in blood supply to the legs in either group, and no side effects recorded in 210 EBOO treatments.
Who carried out the EBOO research?
Four of the six papers come from the group in Siena, Italy, that developed the method. The other two come from clinicians in the United States: doctors at a Santa Rosa, California clinic who measured ozone uptake in 2023, and clinicians at a New York practice who published a case report in 2025.
Does research on other ozone therapy apply to EBO2?
It is useful context. Most of the larger ozone trials used major autohemotherapy, which mixes about 200 mL of blood with ozone in a bag, or injections. EBO2 circulates several liters of blood through a circuit for about an hour, so those results describe related procedures and the EBOO papers describe EBO2 itself.
Will EBO2 work for me?
No study can say how one person will respond, and results vary. The published papers show what researchers measured and reported in the people they studied. A clinic can tell you how many sessions it suggests, and your doctor can help you weigh EBO2 against your health history.
Sources
- Extracorporeal blood oxygenation and ozonation (EBOO) in man. preliminary report. International Journal of Artificial Organs (PubMed), 2000. Peer-reviewed Our notes on this study: Extracorporeal blood oxygenation and ozonation (EBOO) in man. preliminary report
- Necrotizing fasciitis successfully treated with extracorporeal blood oxygenation and ozonization (EBOO). International Journal of Artificial Organs (PubMed), 2002. Peer-reviewed Our notes on this study: Necrotizing fasciitis successfully treated with extracorporeal blood oxygenation and ozonization (EBOO)
- Extracorporeal blood oxygenation and ozonation: clinical and biological implications of ozone therapy. Redox Report (PubMed), 2005. Peer-reviewed Our notes on this study: Extracorporeal blood oxygenation and ozonation: clinical and biological implications of ozone therapy
- Extracorporeal blood oxygenation and ozonation (EBOO): a controlled trial in patients with peripheral artery disease. International Journal of Artificial Organs (PubMed), 2005. Peer-reviewed Our notes on this study: Extracorporeal blood oxygenation and ozonation (EBOO): a controlled trial in patients with peripheral artery disease
- Oxygenation-ozonation of blood during extracorporeal circulation: in vitro efficiency of a new gas exchange device. Artificial Organs (PubMed), 2007. Peer-reviewed Our notes on this study: Oxygenation-ozonation of blood during extracorporeal circulation: in vitro efficiency of a new gas exchange device
- Observed Reduction in Urinary Toxin Excretion With Extracorporeal Blood Oxygenation and Ozonation (EBOO) Treatment in an 88-Year-Old With Chronic Anemia: A Case Report. Cureus (PubMed), 2025. Peer-reviewed Our notes on this study: Observed Reduction in Urinary Toxin Excretion With Extracorporeal Blood Oxygenation and Ozonation (EBOO) Treatment in an 88-Year-Old With Chronic Anemia: A Case Report
- Ozone dialysis delivers three or more times the ozone than other forms of ozone blood treatment. Medical Gas Research (PubMed), 2023. Peer-reviewed Our notes on this study: Ozone dialysis delivers three or more times the ozone than other forms of ozone blood treatment
- Ozonation of blood during extracorporeal circulation. I. Rationale, methodology and preliminary studies. International Journal of Artificial Organs (PubMed), 1999. Peer-reviewed Our notes on this study: Ozonation of blood during extracorporeal circulation. I. Rationale, methodology and preliminary studies
- Ozonation of blood during extracorporeal circulation. II. Comparative analysis of several oxygenator-ozonators and selection of one type. International Journal of Artificial Organs (PubMed), 2001. Peer-reviewed Our notes on this study: Ozonation of blood during extracorporeal circulation. II. Comparative analysis of several oxygenator-ozonators and selection of one type
- Are dialysis devices usable as ozone gas exchangers?. Artificial Organs (PubMed), 2010. Peer-reviewed Our notes on this study: Are dialysis devices usable as ozone gas exchangers?
- Effects of major ozonated autohemotherapy in the treatment of dry age related macular degeneration: a randomized controlled clinical study. International Journal of Ophthalmology (PubMed), 2012. Peer-reviewed Our notes on this study: Effects of major ozonated autohemotherapy in the treatment of dry age related macular degeneration: a randomized controlled clinical study
- Ozone therapy as a treatment for low back pain secondary to herniated disc: a systematic review and meta-analysis of randomized controlled trials. Pain Physician (PubMed), 2012. Peer-reviewed Our notes on this study: Ozone therapy as a treatment for low back pain secondary to herniated disc: a systematic review and meta-analysis of randomized controlled trials
- Fatigue in post-acute sequelae of SARS-CoV2 (PASC) treated with oxygen-ozone autohemotherapy, preliminary results on 100 patients. European Review for Medical and Pharmacological Sciences (PubMed), 2021. Peer-reviewed Our notes on this study: Fatigue in post-acute sequelae of SARS-CoV2 (PASC) treated with oxygen-ozone autohemotherapy, preliminary results on 100 patients
- A systematic review of ozone therapy for treating chronically refractory wounds and ulcers. International Wound Journal (PubMed), 2022. Peer-reviewed Our notes on this study: A systematic review of ozone therapy for treating chronically refractory wounds and ulcers
- A pilot randomized controlled trial of major ozone autohemotherapy for patients with post-acute sequelae of COVID-19. International Immunopharmacology (PubMed), 2024. Peer-reviewed Our notes on this study: A pilot randomized controlled trial of major ozone autohemotherapy for patients with post-acute sequelae of COVID-19
- Efficacy of major ozone autohemotherapy in patients with post-COVID syndrome. Frontiers in Medicine (PubMed), 2026. Peer-reviewed Our notes on this study: Efficacy of major ozone autohemotherapy in patients with post-COVID syndrome
- Combining Ozonated Autohemotherapy with Pharmacological Therapy for Comorbid Insomnia and Myofascial Pain Syndrome: A Prospective Randomized Controlled Study. Pain Research & Management (PubMed), 2022. Peer-reviewed Our notes on this study: Combining Ozonated Autohemotherapy with Pharmacological Therapy for Comorbid Insomnia and Myofascial Pain Syndrome: A Prospective Randomized Controlled Study